Efforts to target angiogenesis associated with the growing GBM using anti-vascular endothelial growth factor (VEGF) monoclonal antibody Bevacizumab has failed to prevent tumor growth, though it does help to reduce cranial edema [14,15,16]. Here, VEGFA is linked to glioblastoma.